Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC)

A prospective study was conducted to identify biomarkers associated with resistance to panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). Patients with previously treated, codon 12/13 KRAS wt, mCRC were prospectively administered panitumumab 6 mg/kg IV q2weeks. Of 34 panit...

Descripción completa

Detalles Bibliográficos
Autores principales: Barry, Garrett S., Cheang, Maggie C., Chang, Hector Li, Kennecke, Hagen F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951343/
https://www.ncbi.nlm.nih.gov/pubmed/26980732
http://dx.doi.org/10.18632/oncotarget.8006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951343/
https://www.ncbi.nlm.nih.gov/pubmed/26980732
http://dx.doi.org/10.18632/oncotarget.8006

Ejemplares similares